1. "Department of Medicine"
Formats
  1. Journal Article (19347)
  2. Meeting Abstract (15822)
  3. Review (1102)
  4. Book Section (924)
  5. Editorial (580)
  6. Research Letter (301)
  7. Conference Paper (299)
  8. Guidelines (285)
  9. Correspondence (226)
  10. Miscellaneous (87)
  11. Book Whole (61)
Groups
  1. Department of Medicine (39034)
  2. Solid Tumor Oncology Division (22035)
  3. Hematologic Malignancies, Division of (13003)
  4. Center for Hematologic Malignancies (10841)
  5. GSK Faculty (10529)
  6. Survivorship Research (9202)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Sergio Giralt (1050)
  4. Miguel-Angel Perales (913)
  5. Clifford Hudis (905)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (642)
  2. 2024 (2141)
  3. 2023 (2451)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2560)

More Years

Publications
  1. Journal of Clinical Oncology (6050)
  2. Blood (3572)
  3. Annals of Oncology (1395)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (890)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6364)
  2. Elsevier Inc. (4610)
  3. American Society of Hematology (3843)
  4. American Association for Cancer Research (2879)
  5. Oxford University Press (2271)
  6. Nature Publishing Group (2080)

More Publishers

Results (39034)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Oncolytic vaccinia virus expressing immune checkpoint blockade antibody as cancer immunotherapeutics
    Meeting Abstract

    Wang, W.; Dai, P.; Yang, N.; Shuman, S.; Yan, W.; Merghoub, T.; Wolchok, J. D.; Deng, L.
    Cancer Research (2018)

    Fulltext@MSK | Save
  • First in human study of activin-A inhibitor, STM434, in patients with granulosa cell ovarian cancer and other advanced solid tumors
    Meeting Abstract

    Tao, J. J.; Liu, J. F.; Rasco, D. W.; Navarro, W.; Haqq, C. M.; Hyman, D. M.
    Cancer Research (2018)

    Fulltext@MSK | Save
  • A phase I dose escalation study of trifluridine and tipiracil (FTD/TPI) in combination with irinotecan (IRI) in patients with advanced gastrointestinal (GI) tumors
    Meeting Abstract

    Varghese, A. M.; Cardin, D. B.; Hersch, J.; Benson, A. B.; Hochster, H. S.; Winkler, R.; Benedetti, F.; Hamada, K.; Berlin, J. D.; Saltz, L.
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC) and ALK kinase domain mutations
    Meeting Abstract

    Shaw, A. T.; Martini, J. F.; Besse, B.; Bauer, T. M.; Lin, C. C.; Soo, R. A.; Riely, G. J.; Ou, S. H. I.; Clancy, J. S.; Li, S.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Biomarkers predictive of response to pembrolizumab in head and neck cancer (HNSCC)
    Meeting Abstract

    Seiwert, T.; Haddad, R.; Bauml, J.; Weiss, J.; Pfister, D. G.; Gupta, S.; Mehra, R.; Gluck, I.; Kang, H.; Worden, F.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Oncogenic KRAS mediates resistance to MET targeted therapy in non-small cell lung cancer (NSCLC) with MET mutations that induce exon14 skipping
    Meeting Abstract

    Suzawa, K.; Offin, M. D.; Kurzatkowski, C.; Liu, D.; Vojnic, M.; Smith, R. S.; Mattar, M.; Khodos, I.; de Stanchina, E.; Sabari, J. K.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Towards automation of germline variant curation in cancer genetics
    Meeting Abstract

    Ravichandran, V.; Shameer, Z.; Offit, K.; Joseph, V.
    Cancer Research (2018)

    Fulltext@MSK | Save
  • OlympiAD final overall survival: Olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)
    Meeting Abstract

    Robson, M. E.; Im, S. A.; Senkus, E.; Xu, B.; Domchek, S.; Masuda, N.; Delaloge, S.; Li, W.; Tung, N.; Armstrong, A.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) plus ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): Identification of TMB cutoff from CheckMate 568
    Meeting Abstract

    Ramalingam, S. S.; Hellmann, M. D.; Awad, M. M.; Borghaei, H.; Gainor, J.; Brahmer, J.; Spigel, D. R.; Reck, M.; O'Byrne, K. J.; Paz-Ares, L.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • CAR T cells secreting an immune checkpoint blockade scFv have enhanced anti-tumor efficacy
    Meeting Abstract

    Rafiq, S.; Yeku, O.; Jackson, H.; Purdon, T.; van Leeuwen, D.; Yan, S.; Wang, P.; Xiang, J.; Liu, C.; Seshan, V.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save